ACCEL Lite: ACC.22 Late Breaker: ADAPT-TAVR Trial -- Edoxaban Versus DAPT For Valve Thrombosis And Cerebral TE After TAVR

What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?

In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.

Related References:

  1. Bogyi M, Schernthaner RE, Loewe C, et al. Subclinical leaflet thrombosis after transcatheter aortic valve replacement. JACC: Cardiovascular Interventions. 2021;14:2643-2656. doi: doi:10.1016/j.jcin.2021.09.019.
  2. Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: An observational study. Lancet. 2017;389:2383-2392. doi: 10.1016/s0140-6736(17)30757-2.

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention

Keywords: ACCELLite, Transcatheter Aortic Valve Replacement

< Back to Listings